Cure MFM13 - The Podcast

EP 12: Journal Club: Putko et al., 2026 | Expanding the Clinical Spectrum of HSPB8 Disease

18 min · 12 de jun de 2026
Portada del episodio EP 12: Journal Club: Putko et al., 2026 | Expanding the Clinical Spectrum of HSPB8 Disease

Descripción

In this Journal Club episode, we discuss the publication by Putko et al. (2026), which describes two patients with HSPB8 variants presenting with overlapping features of myopathy and distal motor neuropathy. The study expands the clinical and pathological spectrum of HSPB8-associated disease and provides new insights into how disease-causing variants may affect HSPB8 function. This episode is ideal for researchers, clinicians, patients, and advocates interested in HSPB8 disorders, myofibrillar myopathy, distal motor neuropathy, and disease mechanisms.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de Cure MFM13 - The Podcast!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

12 episodios

episode EP 8: Clinical features of HSPB8 myopathy artwork

EP 8: Clinical features of HSPB8 myopathy

In this episode, we summarize what is known about Myofibrillar Myopathy type 13 (MFM13), previously referred to as HSPB8 Myopathy. Drawing on nine published case studies, we outline the main clinical features — progressive muscle weakness and atrophy, usually starting in the distal lower limbs and leading to foot drop and steppage gait. In some cases, weakness extends to proximal and axial muscles, occasionally affecting breathing or cardiac function. We also discuss the characteristic pathological findings seen in muscle biopsies: rimmed vacuoles, myofibrillar disorganization, and accumulation of proteins like HSPB8, BAG3, and TDP-43. MRI scans often reveal selective fatty degeneration of paraspinal and leg muscles. Finally, we highlight the key discovery that frameshift mutations in HSPB8 result in an abnormal C-terminal peptide extension, creating a toxic gain-of-function mechanism that disrupts autophagy and cellular proteostasis — defining the molecular basis of MFM13. Learn more about our work at curemfm13.org [http://curemfm13.org], and follow us on Facebook, LinkedIn, X, and Bluesky — just search for CureMFM13.

5 de ene de 202613 min